AIHTA - Publications - Search - Relugolix (Orgovyx®) for the treatment of advanced hormone-sensitive prostate cancer. Update May 2022

Rothschedl, E. and Wolf, S. (2022): Relugolix (Orgovyx®) for the treatment of advanced hormone-sensitive prostate cancer. Update May 2022. Oncology Fact Sheet Nr. 80.

[thumbnail of Oncology Fact Sheet Nr.80_Update.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
91kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WJ Urogenital system > WJ 700-875 Male genitalia
Language:English
Series Name:Oncology Fact Sheet Nr. 80
Deposited on:28 Mar 2022 12:35
Last Modified:24 May 2022 10:37

Repository Staff Only: item control page